Bristol-Myers Squibb Company (NYSE: BMY) came out with earnings at $0.35 EPS and reaffirmed 2008 guidance of $1.36 to $1.46 GAAP EPS and $1.60 to $1.70 non-GAAP EPS. It also maintained a…
Douglas A. McIntyre Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between…
Bristol-Myers (NYSE: BMY) does not see much future in baby food. It is trying to sell its operation to a company where its is a better fit. According to the FT, that…
Those rummaging through the garbage of 52-week low lists are usually bottom-fishing investors or desperate CEOs. But, the list is so broad that it has become a tableau of the market as…
Some large companies, like Bristol-Myers (BMY), has already said that auction-rate securities on their balance sheets may have to be written down now that the market for this paper is illiquid. The…
Douglas A. McIntyre CyDex Pharmaceuticals, Inc. has filed to come public via an IPO in what it lists for filing purposes as up to $50 million in securities sales. It has applied to have the…
On tonight’s MAD MONEY on CNBC, Jim Cramer wanted to look for stocks with both appreciation potential that also offer capital preservation. He, just like us, believes we are starting to price…
Early this week we are running a list of stocks that have been in a turnaround plan, yet the stocks and the businesses haven’t turned around. Could these be the stocks to…
Medarex inc. (NASDAQ: MEDX) is seeing shares slapped in after-hours trading after the company is issuing disappointing news over the hopes for its Ipilimumab Pivotal Trials in patients with Advanced Metastatic Melanoma. …
According to Reuters, Nikon is seeing a sharp increase in demand from LCD makers. Reuters writes that the housing slump will last through 2009 and some home prices will drop 30%. Reuters…
Bristol-Myers (BMY) showed the world its equivalent of the old Soviet "Five Year Plan" today. All of the talk up front was about becoming "a next-generation BioPharma company that pairs the scale…
Douglas A. McIntyre Plavix from Bristol-Myers (BMY) is the medical drug-thinner of choice. According to CNN Money, sales of the drug "totaled $3.4 billion in sales during the first nine months" Now Eli Lilly (LLY)…
Medarex (NASDAQ:MEDX) is seeing shares being hit by a research note where Banc of America initiated coverage with a "SELL" rating. This is a fairly thin volume stock in pre-market trading, but…
We were screening options activity today and something came up that where bets had significantly grown from our prior coverage. Earlier this year we covered some strange biotech options activity after noting…
According to Reuters, Morgan Stanley (MS) plans to start a wealth management business in India. Reuters writes that Alan Greenspan said that US economic growth is slowing. Reuters writes that SAP (SAP)…
